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thrombolysis in acute stroke care
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Christian Kray5 and Richard G Thomson1Abstract
Background: Thrombolytic treatment for acute ischaemic stroke improves prognosis, although there is a risk of
bleeding complications leading to early death/severe disability. Benefit from thrombolysis is time dependent and
treatment must be administered within 4.5 hours from onset of symptoms, which presents unique challenges for
development of tools to support decision making and patient understanding about treatment. Our aim was to
develop a decision aid to support patient-specific clinical decision-making about thrombolysis for acute ischaemic
stroke, and clinical communication of personalised information on benefits/risks of thrombolysis by clinicians to
patients/relatives.
Methods: Using mixed methods we developed a COMPuterised decision Aid for Stroke thrombolysiS (COMPASS) in
an iterative staged process (review of available tools; a decision analytic model; interactive group workshops with
clinicians and patients/relatives; and prototype usability testing). We then tested the tool in simulated situations
with final testing in real life stroke thrombolysis decisions in hospitals. Clinicians used COMPASS pragmatically in
managing acute stroke patients potentially eligible for thrombolysis; their experience was assessed using self-completion
forms and interviews. Computer logged data assessed time in use, and utilisation of graphical risk presentations
and additional features. Patients’/relatives’ experiences of discussions supported by COMPASS were explored
using interviews.
Results: COMPASS expresses predicted outcomes (bleeding complications, death, and extent of disability) with
and without thrombolysis, presented numerically (percentages and natural frequencies) and graphically
(pictographs, bar graphs and flowcharts). COMPASS was used for 25 patients and no adverse effects of use were
reported. Median time in use was 2.8 minutes. Graphical risk presentations were shared with 14 patients/relatives.
Clinicians (n = 10) valued the patient-specific predictions of benefit from thrombolysis, and the support of better
risk communication with patients/relatives. Patients (n = 2) and relatives (n = 6) reported that graphical risk
presentations facilitated understanding of benefits/risks of thrombolysis. Additional features (e.g. dosage calculator)
were suggested and subsequently embedded within COMPASS to enhance usability.
Conclusions: Our structured development process led to the development of a gamma prototype computerised
decision aid. Initial evaluation has demonstrated reasonable acceptability of COMPASS amongst patients, relatives and
clinicians. The impact of COMPASS on clinical outcomes requires wider prospective evaluation in clinical settings.
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Thrombolysis (the breakdown of blood clots using
pharmacological agents; commonly called ‘clot-busting
drugs’) administered within 4.5 hours of acute ischae-
mic stroke onset (caused by a sudden blockage of an ar-
tery supplying blood flow to, or within, the brain)
improves outcome [1]. However, thrombolytic treat-
ment can cause bleeding complications, the most serious
being symptomatic intracranial haemorrhage (SICH)
that typically occurs within 24–36 hours and leads to
clinical deterioration or death [2,3]; although 90 day
mortality is not increased in patients treated with
thrombolysis [4]. Efficacy is time dependent, with earl-
ier treatment associated with increased likelihood of
functional independence (complete recovery or minor
disability) after acute stroke [4,5].
The thrombolysis decision-making context (extreme
time dependent nature of treatment outcome, and the
need to rapidly consider the trade-offs between the likely
long-term benefit and early risk of SICH and its conse-
quences) presents unique challenges for clinicians, pa-
tients and their relatives or proxy [6].
Aggregate-level estimates of the likely balance of bene-
fits and risks of harm from treatment derived from event
rates reported in randomised controlled trials [4,5] and
patient registries [7,8] have been used to support clinical
decision-making about thrombolytic treatment and to
convey probabilistic information on outcome states to
patients/relatives. However, benefit-to-harm ratios differ
as a function of individual patient characteristics due to
variation between patients who fulfil the licensing cri-
teria for treatment. The weighing up of value in treating
any individual patient and communication of this com-
plex information (alongside eligible patients presenting
too late to secondary care and lack of adequate infra-
structure to support delivery of thrombolysis services
[9,10]) is a key reason why thrombolysis is an under-
utilised treatment for acute stroke and door to needle
times (arrival time at hospital to administration of
thrombolysis) are sub-optimal [11,12]. Additional factors
inhibiting the use of thrombolysis include physician-
related factors such as uncertainty about effectiveness,
apprehensions about increased risk of SICH, and unre-
solved issues on relative contraindications for treatment
[5,13-15], and lack of robust data on the likely balance
of benefits and risks of treatment in routine practice as a
function of individual patient characteristics [16].
Evidence-based tools for thrombolysis in acute stroke
such as decision aids [17] are warranted to (i) optimise
treatment rates by assisting clinicians to weigh-up the
potential net benefit in treating any individual patient;
(ii) support clinicians in communicating accurate infor-
mation on risks/benefits and prognosis to patients (or
next of kin/proxy); and (iii) seamlessly support differentapproaches to decision-making about thrombolysis, in-
cluding (where appropriate) engagement of patients/rel-
atives in shared decision-making with stroke clinicians
[6,18]. However, a recent review identified sub-optimal
development (e.g., lack of testing in clinical settings) and
content (e.g., failure to convey balanced synopses of ben-
efits/risks) of decision support, patient information and
risk communication tools for thrombolysis in acute
stroke [6].
The thrombolysis decision-making context in acute
stroke care may be viewed as one in which both clini-
cians and patients/relatives will gravitate toward a pater-
nalistic model of decision-making. However, the optimal
approach to decision-making in emergency contexts
such as acute stroke may vary on a case-by-case basis,
and stroke clinicians are best placed to facilitate the
engagement of patients or their relatives/proxy in a
thrombolysis shared decision-making process as much
as they desire, as appropriate, in accordance with their
preferences and values [19]. Indeed, the decision to treat
acute stroke with or without thrombolysis represents a
choice-based decision under conditions of uncertainty
involving trade-offs between the likely benefit and risk of
harm, which is sensitive to the preferences and values of
patients with regards to treatment and likely outcome
states following acute stroke [20-22]. These conditions
are appropriate for shared decision-making.
Exploratory work (interviews with 37 patients/relatives
and with 23 clinicians involved in decision making and
information provision about thrombolysis) has been re-
ported elsewhere [3]. In summary, this revealed a need:
to strengthen relational (face-to-face) decision support
from clinicians to guide patients/relatives through the
hyper-acute stroke period and thrombolysis decisions;
and for decision support for clinicians to weigh-up the
value in treating any individual patient with thromboly-
sis and for communicating individualised benefits/risks
to patients/relatives.
As self-report obtained from interviews does not always
equate to actual practice, we also used ethnographic
methods, including participant observation and informal
discussions to explored decision-making processes and
practices in situ in three acute units in the north east of
England. Participant observation [129.5 hours] enabled
examination of the way in which individuals organised
and made sense of their experiences, whilst informal
discussions provided clarification. Data analysis drew
on principles of the constant comparative method. Evo-
lution of field notes and coding were undertaken itera-
tively and concurrently with further data collection.
After multiple readings of the data, categories and
codes were derived either directly from the data in the
terms used by participants, with reference to relevant
literature.
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making interactions between patients/relatives and clini-
cians in three acute stroke units revealed clinicians’ had
variable preferences on the ‘‘right time” to raise the pos-
sibility of thrombolytic treatment with patients/relatives
(i.e. before or after CT brain imaging). This reinforced
the need for rapid and pragmatic decision support that
would be accessible across the acute stroke pathway. De-
tailed findings of this phase are available from the corre-
sponding author.
Following a structured process and based on published
guidance [23,24], our objectives (informed by our initial
exploratory work) were to: (i) establish the optimal mode
and content of a decision aid to support eligibility
decision-making about thrombolysis for individual pa-
tients; and clinical communication of personalised infor-
mation on the benefits and risks of thrombolysis to
patients/relatives to support different approaches to de-
cision making in the acute stroke clinical setting; (ii)
identify and describe the key components of a resultant
prototype of a COMPuterised decision Aid for Stroke
thrombolySis (COMPASS); and (iii) establish the usabil-
ity of the prototype decision aid with clinicians and pa-
tients/relatives, in order to refine the user interface and
information content to enhance its acceptability and
feasibility in the acute stroke clinical setting.
Methods
A synopsis of the development process is shown in
Figure 1. Ethical and research governance approval for
each phase (where required) was secured from Re-
search Ethics Committees and participating Hospital
Trusts. Written informed consent was obtained from
clinicians and patients/relatives.
Development phase
Informed by exploratory work, the aims of this phase
were to (i) develop a robust decision analytic model
(DAM) to calculate predictions for acute stroke out-
comes (e.g., death and extent of disability) as a function
of individual patient characteristics; and (ii) identify the
optimal mode of delivery (paper-based or electronic),
form (numerical or graphical risk presentations to con-
vey outcome probabilities derived from the DAM) and
content (language to convey key information such as de-
scriptors for outcome states and time horizons for out-
come probabilities) of a prototype decision aid for
thrombolytic treatment.
Decision-analytic model (DAM)
The development process for the DAM to predict the
patient-specific probability of acute stroke outcomes is
reported in detail elsewhere [25], Briefly, the predictive
equations within the Stroke-Thrombolytic PredictiveInstrument [S-TPI] [26] were used as a basis to construct
the DAM. The S-TPI enables patient-specific predictions
at three months, with and without thrombolysis, for a nor-
mal/near normal outcome (defined as a modified Rankin
Scale (mRS) ≤1, which equates to no symptoms or slight
disability - as a function of seven patient variables); and
a catastrophic outcome (defined as a mRS ≥ 5, which
equates to severe disability/death - as a function of three
patient variables).
There are the differences between predicted outcomes
from the S-TPI and actual outcomes in routine clinical
practice [27,28]. Therefore using data from 2,401 rou-
tinely treated stroke patients from the Safe Implementa-
tion of Thrombolysis in Stroke UK database [7] the
original S-TPI predictive equations were adjusted to en-
sure: (i) consistency between outcomes predicted by the
DAM and actual outcomes of patients treated in routine
practice; and (ii) that definitions of outcomes were rep-
resentative of those typically used in clinical practice
(functional independence [mRS 0 to 2] - complete recov-
ery/minor disability; dependence [mRS 3 to 5] – moder-
ate/severe disability, and death); and (iii) the inclusion of
additional predictors of functional independence from ob-
servational studies of patients treated in routine practice
[29]. Predictions in the DAM for mRS 0 to 2, 3 to 5 and
death in untreated patients were validated using untreated
patient data (N = 5,715) from the Virtual International
Stroke Trials Archive [30].
A scoring model derived from patients treated with
thrombolysis in routine practice [31]) was selected to
calculate patient-specific predictions of risk of SICH. A
suitable predictive equation for outcomes following
SICH could not be identified in the literature. Therefore,
the subsequent impact of SICH on outcomes at three
months used proportions of patients that would likely be
mRS 0 to 2, 3 to 5 and dead following SICH [32].
Interactive group workshops
A suite of draft paper-based tools (Additional file 1)
were developed to convey the outcomes generated by
the DAM (informed by a literature review of currently
available tools, published elsewhere [6] and guidance on
presentation of outcome probabilities [33]) to support
eligibility decision making about thrombolysis for indi-
vidual patients (structured look-up tables and tables of
decisions rules for different levels of net benefit from
thrombolysis) and clinical communication of persona-
lised information on the risks/benefits of thrombolysis
to patients/relatives (clustered and stacked bar graphs,
pictographs and flowchart diagrams).
Draft paper-based tools were presented within inter-
active workshops (mixture of demonstration, open
discussion and small group exercises) with 12 stroke clini-
cians (five stroke physicians, two emergency department
1a: Interview Study
Revisions to Decision Analytic Model
Draft paper-based decision support and risk communication tools
4: Feasibility of a beta prototype in the actual hyper-acute stroke setting
2b: Review of Tools 
3a: Interactive group workshops: 
1) Stroke clinicians
2) Stroke patients and relatives
1b: Ethnographic Study
Development of computerised alpha prototype decision aid
Revisions to alpha prototype 
Usability of the prototype with 
stroke patients and relatives 
as a risk presentation tool
Usability of the prototype with 
clinicians as a clinical decision
making and risk presentation tool
2a: Decision Analytic Model
Revisions to risk presentations
3b: Usability testing of computerised 
prototype in non-clinical settings
DEVELOPMENT PHASE
TESTING PHASE
EXPLORATORY PHASE
Figure 1 Overview of the development process.
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a history of previous stroke, and seven of their relatives.
Field notes on salient points and reactions of the partici-
pants were recorded, and summarised for discussion
within the research team to inform the development of an
alpha prototype of the decision aid for usability testing.
Development of alpha prototype
One of the authors (DN), a computing science graduate
with six years of programming experience (with support
from a senior computing scientist, CK) developed thesoftware, spending approximately 10 weeks [full-time
hours] to develop the alpha prototype of COMPASS.
The DAM was embedded within an alpha prototype of
COMPASS, which was developed on an iPad® mobile
digital device (Figure 2) for the following reasons: rapid
input of patient information by clinicians; the large LCD
touch sensitive screen facilitates accessibility and inter-
pretation of the risk presentations by clinicians and pa-
tients/relatives; and for ease of deployment at the point
of care without the need for additional peripherals or in-
tegration with existing hospital IT systems.
Figure 2 Alpha prototype of COMPASS.
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participants’ preferences on their form and content
(identified in interactive workshops) were embedded in
the prototype to convey outcome probabilities for short-
term acute stroke outcomes.
A series of user interface features were incorporated
into the prototype, informed by design principles from
human computer interaction [34]: (i) patient details and
outcomes all displayed on one screen (without scrolling)
to facilitate calculation/viewing of predicted clinical out-
comes; (ii) instant updating of patient details when users
changed one or more entered patient values to expedite
re-calculation of outcomes; (iii) instant validation for
continuous patient details in accordance with the licens-
ing criteria for thrombolysis (green ticks and orange ex-
clamation marks appear to the right of text boxes to
indicate that entered continuous values are within or
outwith the licensing criteria respectively, and red
crosses to the right of text boxes to indicate that invalid
values have been entered); and (iv) prompts and warning
messages when entered values are invalid or outwith the
licensing criteria for thrombolysis.
Populating the patient details (which would be under-
taken by the treating clinician) and selecting ‘calculateoutcomes’ generates outcome probabilities presented nu-
merically (percentages and natural frequencies) and
graphically (using pictographs, clustered bar graphs and
a flowchart diagram juxtaposed with stacked bar graphs).
Predicted net benefit and harm from thrombolysis (abso-
lute difference between probability of independence with
and without treatment) is presented in a summary box
at the bottom left of the screen.Usability testing phase
Informed by previous phases, we aimed (i) to test usabil-
ity of an alpha prototype of COMPASS with clinicians
and patients/relatives, in order to optimise the user
interface and information content to enhance practical-
ity, acceptability and usability in the actual acute stroke
setting; and (ii) to establish the acceptability and feasibil-
ity of a beta prototype in the clinical setting based on ex-
periences of clinicians and patients/relatives.
Interactive usability testing of the prototype was
undertaken by 12 stroke clinicians (five stroke physi-
cians, five emergency department physicians, two stroke
nurse practitioners), plus five patients with a history of
stroke and four of their relatives.
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elicit clinicians’ preferences on screen appearance and
layout (portrait [vertical] orientation with radio buttons
for toggling between risk presentations; and two in land-
scape (horizontal) orientation with either radio buttons
or tabs for toggling between risk presentations); chrono-
logical order of patient details; labels used to denote pa-
tient details; and content of risk presentations. Clinicians
then used a functional prototype on the iPad, which was
customised in accordance with each clinician’s prefer-
ence on screen appearance/layout and content identified
during paper-prototyping. Clinicians were encouraged to
use COMPASS in a simulated way (e.g. entering data on
hypothetical cases), and their comments and reactions
during their interactions with the functional prototype
were recorded by the two researchers (DF and DJN).
The session ended with a brief interview about potential
benefits/problems with use of COMPASS in clinical
settings.
Patient/relative usability testing involved a demonstra-
tion of the risk presentations (paper and iPad screen
showing two patient scenarios - one with clear and one
with borderline benefit from treatment), followed by a
brief interview to elicit their views and preferences on
mode (paper or computerised presentation); type of risk
presentation (e.g., pictograph); order, complexity and
possible improvements that could be made to the risk
presentations; and potential benefits/problems with use
of the risk presentations during the hyper-acute period
of stroke.
All data collected during usability testing were dis-
cussed with the research team in regular project meet-
ings to inform production of a beta prototype of
COMPASS and design of a subsequent feasibility study
in the clinical setting.Feasibility study
Over a six month period, 19 stroke physicians and stroke
nurse practitioners (within three acute stroke units in
England providing round the clock thrombolysis) were
given access to COMPASS on iPad® mobile digital de-
vices and a website. Each site was also supplied with a
wireless printer. One of the authors (DF) provided clini-
cians with a face-to-face tutorial on use of COMPASS. A
video tutorial on the fundamental operations of COM-
PASS was embedded within the iPad.
Clinicians used COMPASS pragmatically (i.e. at the
discretion of the treating clinician; this approach to use
of COMPASS was informed by discussions with clinical
teams prior to the feasibility study) within their acute
stroke pathway to support clinical decision-making for
thrombolysis, and/or communication of the risks/bene-
fits of treatment to patients/relatives. Paper-based self-completion forms (Additional file 2), interviews and
computerised data logging (iPad) captured information
on the use of COMPASS by clinicians. Interviews with
patients/relatives explored their experiences of discus-
sions about thrombolysis supported by COMPASS. In-
terviews were audio recorded and transcribed verbatim
for the purposes of analysis.
Interviews with clinicians and patients/relatives were
conducted by one researcher (DF), and followed a topic
guide (see below). Interviews with clinicians took place
in private offices within acute stroke units as soon as
practicable following use of COMPASS. All interviews
with patients/relatives who agreed to participate in an
interview all took place in their homes within (~7+/−2
days) after the stroke/thrombolysis decision making dis-
cussion supported by COMPASS.
Interview guides used in the feasibility study
A. Clinician Interviews
General issues connected with their experience of
the consultation using the decision aid
 As an introductory question - What is the present
situation like (eligibility assessment and risk
communication) without the decision aid?
 How did eligibility selection/consultations using the
decision aid compare to a conventional eligibility
assessment/consultation?
Use of the decision aid for eligibility selection
 Did you use the decision aid for eligibility selection?
 Did the outcomes generated by the decision aid help
you make eligibility decisions?
 What are the benefits of using the decision aid for
eligibility selection?
 What are the problems with using the decision aid
for eligibility selection?
 If you did not use the decision aid for eligibility
selection-could you please explain why?
Role of the risk presentation tools
 Did you use the decision aid for risk
communication?
 What are the benefits of using the decision aid for
risk communication?
 What are the problems with using the decision aid
for risk communication?
 What risk presentations and strategies did you use?
 What information did you feel that you managed to
convey to patients/relatives using the decision aid?
 How did patients/family members react to the risk
presentations?
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communication-could you explain why?
Acceptability of the decision aid and data collection
methods
 In your view what are the barriers (and facilitators)
to the use of the decision aid and its integration
within the current care pathway for thrombolytic
treatment in acute stroke?
 How could the support website and decision aid be
improved?
 How could the methods of data collection be
improved?
B. Patient and Relative Interviews
General issues connected with their experience of
the consultation
 What information were you given about
thrombolysis (clot-busting treatment) for stroke?
 Were you involved in the decision to have
clot-busting treatment?
 How did you feel about being involved in the
decision about clot-busting treatment?
 What things did you take into account when making
your decision?
Role of the risk communication tools:
 How did the doctor/nurse explain the benefits/risks
of clot-busting treatment to you?
 Were you shown risk and benefit information using
pictures?
o If yes, could you tell us about this? (elicit
information on mode [paper or on iPAD screen]
and form (e.g., pictograph)
 Did the information on risks/benefits of clot-busting
treatment help you to understand certain things?
What? How?
 Was there too much information? Was there
anything that was not clear?
 Did the information on risks/benefits help you make
a decision? If yes, how?
 Would you have liked a copy of the information on
benefits/risks of clot-busting treatment to keep? If
yes why?
 What other information/support would have been
helpful to you?
Interview data were subjected to an iterative conceptual
content analysis [36] by one member of the research team
(DF). A priori [based on topic guides] and emergent cod-
ing were used to summarise key themes for discussionwith the research team who served as a challenge forum
on the integrity of the analysis. Quotations from partici-
pants were used to represent key themes, and to enable
the reader to adjudicate on the robustness of the interpre-
tations. An integrative analysis of all data collected on use
of COMPASS (paper-based self-completion forms, inter-
views and computerised data logging) were considered
alongside our previous development work and relevant lit-
erature to inform production of a gamma prototype.
Results
Decision-analytic model
A decision-analytic model (DAM) was constructed to pre-
dict the patient-specific probability of acute stroke out-
comes at three months, with and without thrombolysis,
including risk of SICH and subsequent impact of SICH
(Figure 3). The DAM also includes patient-specific predic-
tions of risk of SICH for patients treated with thromboly-
sis (using a scoring model derived from patients treated
with thrombolysis in routine practice [31]), including the
subsequent impact of SICH on outcomes at three months
with reference to proportions of patients that would be
mRS 0 to 2, 3 to 5 and dead following SICH [32].
Interactive group workshops
Clinicians stated that paper-based decision support was
‘unwieldy’ and computerised methods were likely to be
the most efficient mode of delivery within the hyper-
acute period of stroke. Computerised methods were con-
sidered the most efficacious mode of delivering decision
support, and the draft risk presentations were consid-
ered useful for conveying short-term outcome probabil-
ities to patients/relatives.
Presentation of short-term outcomes in patient/rela-
tive friendly-language (e.g., “clot-busting treatment” for
thrombolysis) within verbal presentations by trusted cli-
nicians, supported by using pictographs or clustered bar
graphs (showing outcomes with and without thrombo-
lytic treatment - expressed as percentages and natural
frequencies with ‘out of 100 patients’ as the denomin-
ator) were identified as feasible methods for conveying a
balanced presentation of the benefits and risks of
thrombolytic treatment to patients/relatives. In contrast,
long-term outcomes (e.g., life expectancy) elicited strong
negative reactions from patients/relatives (i.e., highly
likely to elicit fear).
Usability testing
Clinicians reported potential benefits in enhanced
decision-making about thrombolysis for individual patients
within the licensing criteria, including better risk commu-
nication and informed consent. Clinicians expressed a
clear preference for pictographs as a risk presentation/
communication tool.
Figure 3 Summary of Decision Analytic Model embedded within COMPASS. Predictions for mRS 0 to 2, 3 to 5 and death in untreated patients
were validated using data (N = 5,715) from untreated patients recorded in the Virtual International Stroke Trials Archive.
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ceptance of the outcome probabilities; capability of pa-
tients/relatives to understand the risk presentations;
conveying an artificial level of certainty leading to poten-
tial problems with providing individualised information
to patients/relatives; and the potential to interrupt clin-
ical flow, and ultimately delay decision-making and
treatment.
The language used to describe the options (treatment
with and without thrombolysis) and outcome states (in-
dependence, dependence, death and SICH) conveyed in
the risk presentations were comprehensible to patients/
relatives. Patients/relatives revealed mixed preferences
for paper-based or computerised risk presentations. A
greater degree of involvement in the decision-making
process and increased reassurance about a decision to
consent to treatment, both before and after treatment (if
they were provided with a copy of the risk presentations)
were mentioned as benefits of the risk presentations. It
was evident from comments made by patients/relatives
that the risk presentations facilitated an understanding
(i) of the more immediate risk of SICH associated with
thrombolytic treatment and outcomes following SICH;
(ii) of the absolute increase in functional independence
(referred to colloquially as ‘hope’ or ‘life’) associated with
treatment; and (iii) that overall mortality was equivalent
with and without thrombolysis.
A majority considered it important to present a bal-
anced synopsis of the risks and benefits of treatment, al-
though there were mixed views on the value of conveying
risk of SICH (especially when this was ‘small’; 1 in 100patients). Several expressed a preference on outcomes pre-
sented in the order of independence, dependence and
death. Concerns were raised by one patient and relative
that the risk presentations may convey too much informa-
tion during a highly stressful period (particularly the flow-
chart diagram), and emphasised that a focus could be
placed on the summary box showing the likely net benefit
from thrombolysis.
Usability testing informed amendments to the user
interface, graphical risk presentations and inclusion of
additional features (Table 1) to produce a beta prototype
(Figure 4).
Feasibility study
Data collected on contact forms and automatically
logged data on use of COMPASS by clinicians are sum-
marised in Table 2. Ten (out of 19 given access) clini-
cians reported using COMPASS for 25 patients (17
treated and eight not treated with thrombolysis) via the
iPad (n = 23) or the web (n = 3) over the six month study
period. COMPASS was used with 15 patients to support
clinical decision-making or to obtain more detail on
likely patient benefit after a decision to offer thromboly-
sis. Risk presentations generated by COMPASS were
shared with 14 patients/relatives (predominately with
relatives [n = 10] via the iPad screen [n = 11] using picto-
graphs [n = 14]). In three cases this was before treatment
to support informed consent, and in ten to augment un-
derstanding of the decision made about thrombolysis
after treatment. Pictographs were used to facilitate un-
derstanding of a decision not to offer thrombolysis to
Table 1 Amendments to alpha prototype of COMPASS resulting from usability testing
Amendment Rationale
• Landscape orientation with ‘tabs’ to switch between risk presentations • Analogous to existing systems (e.g., Internet explorer)
• Headers ‘inputs’ and ‘outcomes’ amended to ‘Patient details’ and
‘Predicted clinical outcomes’ respectively
• Reflects the language used in clinical practice, and to reduce perception
of an artificial level of certainty
• Order of patient details (demographics, medical history, blood results,
examinations and CT scan)
• Sequence that information ‘typically’ becomes available during the
hyperacute period
• Amendments to labels for patient details and menu of operational
definitions for patient details
• Avoid ambiguity, expedite data entry and security with data validation
• Separate text boxes for entering information on stroke onset time and
time likely to treat
• Security with data validation - with only one text box for ‘stroke onset
time to treatment’ there is no reference point for stroke onset time or an
explicit target treatment time
• Automatic deletion of entered values when editing (and clearing risk
presentation to indicate that calculation of outcomes needs to be
repeated)
• Security with data validation by reducing risk of data mis-entry/accidental
changes to patient details
• Amendments to risk presentations: • Consistency with preferences of clinicians and patients/relatives
o use of the letter H to denote SICH and impact of SICH in the
pictograph for treated outcomes
o re-ordering information in the clustered bar graph and flowchart
diagram (independence, dependence, death)
• Inclusion of additional features: • Increased acceptability and usability - enhanced governance/consent
processes; and facilitating case review and use as a clinical training aid
o weight conversion tool (Stones/lbs to kg);
o NIHSS calculator;
o ‘timeline’ function showing decrease in likely benefit from treatment as
a function of stroke onset time to treatment;
o ability to save and print the risk presentations
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clinical training aid with an emergency medicine phys-
ician to show the likely outcomes if a patient had arrived
within the time window for thrombolysis. COMPASS
was also used to assess the potential (missed) outcomes
for a patient that had not been referred to the stroke
team. Opportunities to use COMPASS, but where it was
not used by clinicians were reported on eight occasions.
No adverse effects of use of COMPASS were reported.
The National Institutes of Health Stroke Scale
(NIHSS) calculator (quantitative assessment of stroke-
related neurologic deficit [37]), weight convertor tool
and save function were each used for six cases. For five
cases the timeline (showing decrease in net benefit from
thrombolysis as a function of increasing stroke onset
time to treatment) was used. The print function was
used infrequently (n = 3). On three occasions data entry
errors were detected by COMPASS and error messages
given.
Time in use (first data input to calculation of out-
comes following result of brain imaging to populate the
data field ‘signs of current infarction on CT scan’) ranged
from 0.7 to 30 minutes; the median (IQR) was 2.8 mi-
nutes (7.6 minutes).
Clinicians reported benefits in clinical decision-
making: e.g. “clear presentation of the risks andbenefits…..able to look at the charts and say yes we
should do this or … confirming your no’ (Stroke Phys-
ician [SP] 2), especially for patients at extremes of the li-
censing criteria; e.g. the lower end of the NIHSS:
“confirmation that this low level of NIHSS had benefit”
(SP 6).
Benefits in risk communication were emphasised, in
particular visual presentation of data:
“feel comfortable saying actually five more people
would benefit, there’s no change in risk of death”
(Nurse Practitioner 1).
“there’s no significant additional mortality to the
natural history’ …. that’s very, very difficult
information to communicate without that sort of
pictogram” (SP 4).
One clinician emphasised the value of graphical risk
presentations to support provision of post-decision in-
formation to relatives who were not present at the time
of treatment: “useful to tell the family and then explain
what that treatment was and why it was or wasn’t a
clear decision” (SP 6).
Improved support to clinical governance and medico-
legal issues were highlighted as benefits of COMPASS:
Figure 4 Beta version of COMPASS.
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very high quality conversation but also puts our focus
of mind that this is an important piece of managing
the patient in that very difficult time” (SP 3).
“it then becomes part of the record which I think will
stand up better in court” (SP 4).
One clinician encountered difficulties with use of the
bar graph. Nevertheless, clinicians generally considered
that relatives found the risk presentations [pictographs]
beneficial for risk communication and enhancing en-
gagement: “They get more engaged rather than just
dazed when we explain the benefit and risk and they get
to see something and they’re more focused on what we’re
discussing” (SP 3).
Seven themes on barriers to use of COMPASS were
identified from interviews with clinicians and data from
self-report forms: (i) when stroke physicians were involved
in remote consultations with emergency medicine physi-
cians; (ii) iPad not charged/unavailable for use; (iii) com-
plex cases involving a consideration of variables not listed
in COMPASS; (iv) inexperience with using computertechnology/iPad; (v) confidence in accepting data on out-
comes for patients at the extremes of the licensing criteria;
(vi) patients clearly within the licensing criteria for treat-
ment; and (vii) clinicians’ reservations about sharing infor-
mation on ‘large’ probabilities of death/poor outcomes
with patients/relatives.
Interviews with patients (n = 2) and relatives (n = 6)
described how features of the graphical risk presenta-
tions (juxtaposition of displays with and without treat-
ment and use of colour) enhanced their comprehension
of the risks/benefits of treatment, including increased
comfort with providing consent for thrombolysis and in-
volvement in decision-making:
“especially in such stressful circumstances, someone
just quoting figures at you one in this and two in
that……..you can compare the pictures alongside each
other rather than somebody saying you know well 20%
this and 25% that” (Relative 4).
“It gave me as you say a visual sort of explanation of
it which I couldn’t have taken in mentally, not at that
time” (Relative 2).
Table 2 Data on use of COMPASS in the clinical setting
Generic pattern of use by clinicians (N = 10) F (%F)
Cases
Treated patients 17
Untreated patients 8
Overall 25
Platform
iPad 23
web 3
Category of use
Clinical decision making 12
Obtain more detail on likely patient benefit 3
Risk presentations shared with relatives/patients 14
Other clinical activity 2
Opportunity for use, but not used
Decision aid was unavailable 1
Not used for other reason 7
Risk presentations shared with patients/relatives (N = 14)
Period when risk presentation was shared
Before infusion 3
After infusion 10
Justify decision not to offer thrombolysis 1
Risk presentation shared with:
Patient 1
Relative(s) 10
Patient and relative(s) 3
Mode of risk presentation
iPad 11
Paper 3
Form of risk presentation
Pictograph 14
Clustered bar chart 1
Flowchart/stacked bar graph 0
Logged data, N = 21 cases
Risk presentations viewed
Pictograph 21
Clustered Bar Graph 9
Flowchart and stacked bar graphs 6
Use of additional features
NIHSS calculator 6
Weight convertor 6
Save function 6
Timeline 5
Print function 3
Time in use (minutes) 2.8 (7.6)*
*Median (IQR).
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(Relative 3).
One relative would have preferred one-to-one verbal
presentation only and another would have preferred not
to have received information on death: “I don’t think
that the information about one in however many within
a year dies……. I thought ‘I don’t really need that infor-
mation at the minute” (Relative 4)
The value of being given a paper copy of the risk pre-
sentations to keep was noted by one relative (it enabled
reflection on the consent discussion and provided re-
assurance that the most appropriate decision had been
made): “I was able to just reflect and say okay I’ve done
the right thing for my wife” (Relative 3)
Findings and subsequent discussions within the re-
search team informed amendments to COMPASS
(Table 3) to produce a gamma prototype (Figure 5). De-
tails of the full range of additional features in the
gamma prototype are shown in Additional file 3.
Discussion
This is the first study to develop and pilot test the use of
a decision aid for treatment of acute stoke with intraven-
ous thrombolysis in the clinical setting. COMPASS has
been designed in an effort to support: (i) the clinical de-
cision to offer thrombolysis based on individual differen-
tial effectiveness, (ii) clinicians with a mechanism to
rapidly communicate the probability of a good clinical
outcome and the risks of thrombolysis with patients/rel-
atives in order to respect their autonomy; and (iii) clini-
cians to assess the degree to which patients/relatives
desire to engage in thrombolysis decision-making prior
to making the decision to administer treatment.
The findings of the feasibility study provides evidence
that COMPASS may have tangible benefits in the clinical
setting for supporting patient-specific eligibility selection
for thrombolysis in the treatment of acute ischaemic
stroke and personalised risk communication, including
support for recording of decision-making. The decision
aid also has potential use as a clinical training aid.
COMPASS supports ‘instant validation’ of entered pa-
tient values on continuous variables in accordance with
the current licensing criteria for thrombolysis. Various
scenarios (based on real or simulated patients) can be
used to facilitate learning about assessment of eligibility
for thrombolysis, including absolute and relative contra-
dictions for treatment within the current licensing cri-
teria and likely clinical outcomes at three months after
stroke. The graphical risk presentations can also be used
to develop skills in communicating benefits and risks to
patients and their relatives in the acute setting. Further-
more, additional features such as the NIHSS and dosage
calculators can be used to facilitate training on assessment
Table 3 Amendments to the beta version of COMPASS following feasibility testing in the clinical setting
Amendment Rationale
Revisions to decision analytic model • Enhanced clinical face validity of predicted outcomes and
accuracy of predicted risk of SICH
o Time horizon of three months for predicted outcomes (independence,
dependence and death)
o Inclusion of new scoring model for risk of symptomatic intracranial haemorrhage,
which necessitated the addition ‘current use of Clopidogrel’ and ‘history of
hypertension’ to the list of patient details
Inclusion of the additional features: • Enhanced clinical utility and interpretability
o rt-PA dosage calculator, with a pop-up icon displaying detailed dosage figures
o Glucose conversion tool (mg/dl to mmol/L)
o Line graph incorporated into timeline function to show more clearly the decrease
in likely benefit from thrombolysis as a function of stroke onset time to treatment
Amendments to list of patient details and warning messages: • Enhanced clinical face validity and usability, reduced risk of
data entry errors and security with data validation
o Amended warning for entered NIHSS values < 5 and > 25: “The license states that
a minor neurological deficit or severe stroke as assessed clinically (NIHSS > 25) are
relative contraindications to treatment with rt-PA. For patients with mild stroke the
risks may outweigh the expected benefit. Patients with very severe stroke are at
increased risk of intra-cerebral haemorrhage.”
o Rules for number of integers that need to be entered for onset time, target
treatment time, age, systolic blood pressure, glucose and weight); e.g. users must
enter >1 and <4 integers for systolic blood pressure
o Signs of early infarction on CT/MRI scan replaced with ‘Signs of current infarction
at baseline imaging’
o Larger text boxes for two patient details: systolic blood pressure and glucose (BM)
o Added flexibility for stoke onset time and target treatment time – users can enter
values in multiple formats (hhmm, hh:mm, hh.mm)
Amendments to the risk presentations: • Enhanced interpretability of predicted clinical outcomes
o Addition of time horizon for SICH ‘within 24–36 hours after clot-busting treatment’
o Added to whitespace area: “Please note: predicted clinical outcomes at 3 months
apply to patients with pre-stroke modified Rankin scores of 0 to 2”
Other amendments to the user interface: • Enhanced usability and
o Inclusion of ‘acute ischaemic stroke’ to header ‘predicted clinical outcomes’ • acceptance of the decision aid
o Disabled copy/paste function (tablet computer only)
o Inclusion of readability statistics and production date
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infusion (ml/hr) and number of 50 mg rt-PA vials needed.
Finally, the extreme time dependency of treatment and
the need for expeditious door to needle times can be mod-
elled by using the timeline function.
The benefits of involving patients/relatives and clini-
cians in an iterative co-design and development process
(with reference to evidence-based methods to present a
balanced synopsis of probabilistic information on bene-
fits/risks) ensures that the mode, form and information
content of COMPASS is responsive to users’ prefer-
ences and the complexities of the decision context
[6,33]. Furthermore, it enabled the development of a
different type of decision aid to those used in non-
emergency settings, and which addressed shortcomings
of currently available tools for supporting decision-making and patient understanding in the treatment of
acute stroke with thrombolysis [6].
The ability of COMPASS to rapidly present indivi-
dualised outcome probabilities has potential benefits
over aggregate-level estimates to support eligibility
decision-making in two ways: (i) enhanced comfort/
confidence with thrombolysis decisions, in particular
for patients at the extremes of the licensing criteria;
and (ii) minimising ‘black and white’ decision-making
(based exclusively on whether or not a patient is within
the licensing criteria) by emphasising a need to con-
sider the magnitude of likely net benefit/risk for any in-
dividual patient. This represents more effective and
appropriate patient selection in comparison to target
driven or binary decision-making based on licensing
criteria alone.
Figure 5 Gamma version of COMPASS.
Flynn et al. BMC Medical Informatics and Decision Making  (2015) 15:6 Page 13 of 15Time in use was within acceptable parameters. The
outlying value of 30 minutes represents inputting of ini-
tial demographic data then entering once CT scan had
been confirmed (as opposed to waiting for CT scan to
be confirmed before populating all data fields). Any
negative impact on clinical flow/door to needle time (ar-
rival at hospital to administration of treatment) which
may delay treatment decision-making and thrombolysis
(due to additional time needed to explain the content of
risk presentations to patients and relatives) can be mini-
mised by using COMPASS in parallel to other processes
along the thrombolysis pathway so that delay is mini-
mised e.g. whilst waiting for brain imaging.
Use of COMPASS in the feasibility study after treat-
ment might suggest a primary use to justify decisions
in accordance with a paternalistic model of decision-
making. However, the majority of cases had clear net
benefit and clinicians reported enhanced communication
with patients/relatives, including conveying risk of SICH
which patients may find difficult to process [20]. The lat-
ter is important, as acute stroke is often experienced by
patients/relatives as a traumatic event, which can im-
pede their capacity to understand verbal information
conveyed by clinicians [3].Comprehension of potential benefit versus harm of
treatment, including increased comfort with providing
consent for thrombolysis and engagement in decision-
making were identified as possible benefits of the risk
presentations with patients/relatives. The use of picto-
graphs to convey probabilistic information is consistent
with research reporting on their acceptability in people
with differing health literacy skills, including facilitating
the acquisition of verbatim (specific probabilistic infor-
mation) and gist knowledge (general impression) [38].
Issues related to clinicians’ acceptance of probabilities
highlights situations where engaging patients/relatives
(where appropriate) in shared decision making with cli-
nicians may be the most appropriate approach. Out-
comes generated by COMPASS represent choice-based
decisions under conditions of uncertainty involving
trade-offs between the likely long-term benefit (reduced
risk of significant post-stroke disability) and short-term
risk of SICH and its consequences, which are likely to
be valued differently by individual patients/relatives
[20-22]. However, there are varying individual prefer-
ences for information on thrombolysis (e.g. for mortality
identified in our study) and involvement in decision-
making [20,21].
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relational decision support practices by providing an add-
itional mechanism to help clinicians to guide patients/rel-
atives through the thrombolysis decision-making process,
including augmenting patient/relative autonomy by facili-
tating their active involvement in thrombolysis decision-
making.
Generalisability of our results must be made cautiously
due to the limited sample sizes of patients/relatives and
clinicians in the feasibility study. Analysis of the inter-
views was also performed by a single author (DF), al-
though any potential bias was minimised by engaging the
other authors in the role of peer reviewers/debriefers (i.e.,
emerging themes were discussed within group meetings)
to ensure the conceptual interpretations were a credible
account of the participants’ experiences.
A prospective evaluation in other centres and health
care systems (along with skills training for clinicians on
risk communication), with larger samples of stroke clini-
cians and patients/relatives, to assess the utility and im-
pact of the gamma prototype on thrombolysis rates,
clinical outcomes, healthcare utilisation and safety, with-
out compromising door-to-needle time is warranted.
Further work is also needed to optimise use of COM-
PASS as a clinical training aid, and how it could be em-
bedded/adapted for use within the telemedicine model
of acute stroke care, including adoptability within other
systems designed to facilitate rapid assessment of patient
eligibility for thrombolysis.
Gamma prototype versions of COMPASS have been
developed for smartphone, desktop and tablet computers
to address issues related to accessibility. Relevance and
quality of information content of COMPASS may dimin-
ish rapidly over time due to availability of new data on ef-
fectiveness of thrombolysis, including information systems
designed to deliver decision support [6]. Therefore, to
address these threats to ‘temporal validity’ there is a re-
quirement to secure resources for supporting routine
maintenance and updating of information content to
support protracted use of decision aids such as COM-
PASS, including weighing up the pros and cons of
implementation informed by prospective evaluation
from randomised trials or real-time service evaluations
[6,24,39].
Conclusions
COMPASS may have tangible benefits in supporting
patient-specific clinical decision-making about thromb-
olysis, and in risk communication with patients/relatives
to augment understanding of thrombolysis and support
with recording of thrombolysis decisions, including
where appropriate increasing engagement of patients/
relatives in shared decision making. Acceptability and
functionality of COMPASS in other centres and healthcare systems (with larger samples of stroke clinicians and
patients/relatives); including impact on door-to-needle times
and thrombolysis rates requires prospective assessment in
the clinical setting.
Additional files
Additional file 1: Draft paper-based tools. Examples of draft paper to
support eligibility decision making about thrombolysis for individual
patients (structured look-up tables and tables of decisions rules for
different levels of net benefit from thrombolysis); and clinical communication
of personalised information on the risks/benefits of thrombolysis to
patients/relatives (clustered and stacked bar graphs, pictographs and
flowchart diagrams).
Additional file 2: Paper-based self-completion form. Paper-based
self-completion form used to collect data on use of COMPASS in the
clinical setting by clinicians during the feasibility study.
Additional file 3: Overview of Additional Features in COMPASS.
Additional features in the gamma prototype version of COMPASS.
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